Seattle, WANCT07414511Now EnrollingIRB Ready

Hemophilia A Clinical Trial in Seattle, WA

Access cutting-edge hemophilia a treatment through this clinical trial at a research site in Seattle. Study-provided care at no cost to qualified participants.

Sponsored by University of Washington

Quick Self-Assessment

See if you qualify for this Seattle location

Preparing your pre-screening questions…

Expert Care in Seattle

Access hemophilia a specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hemophilia a treatment provided free

Apply for This Seattle Location

Check if you qualify for this hemophilia a clinical trial in Seattle, WA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Seattle

    Convenient for WA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Seattle site if eligible
  4. 4Begin participation

About This Hemophilia A Study in Seattle

This study longitudinally observes the intergenerational (mother-child) continuum in hemophilia A from pregnancy through early childhood. Because the study follows mother-child pairs, the study includes both a maternal cohort and a pediatric cohort. Each cohort has a primary goal: for the mother with a severe hemophilia genotype, the overarching primary goal is to understand the risks for pregnancy-associated bleeding and postpartum hemorrhage (PPH); for the child, the overarching primary goal is to understand the risks, timing, and circumstances of development of anti-FVIII antibodies. From a longitudinal perspective, risks for both bleeding in the mother and anti-FVIII antibody development in the child are expected to be influenced over time by genetic and environmental factors that begin early in (or before) pregnancy. Enrollment of blood relatives is offered to improve power to better understand inherited contributions to bleeding and inhibitor development in the mother-baby pairs.

Sponsor: University of Washington

Who Can Participate

Inclusion Criteria

Pregnant individuals who meet the following criteria are eligible for enrollment as study participants:
Currently pregnant and prior to 37 weeks gestation
Known to have or at-risk of having a severe hemophilia A genotype
Pregnant with at least one fetus at-risk of inheriting severe hemophilia A
Ability to understand and willingness to provide informed consent
18 years of age or older Before the 38th week of pregnancy, enrolled participants must meet all the following criteria to continue to remain in the study:
The pregnant mother has a severe hemophilia A genotype.
A fetus is determined to have a \>/= 25% risk of inheriting severe hemophilia A, or prenatal testing indicates a fetus is affected by severe hemophilia A.
No other discontinuation criteria have been identified. Pediatric Continuation / Inclusion Criteria: Eligibility of the child to continue is assessed by age 8 weeks. Mother-child pairs in which a child meets the following criteria will remain in the study:
Severe hemophilia A defined by a baseline FVIII:C \< 0.01 IU/mL (or FVIII:C \< 1%) or a genotype predicted to cause severe hemophilia A
Born to a mother participating in the study Thereafter, mothers and their children will continue in the study as long as no new discontinuation criteria occur. Inclusion Criteria for Blood Relatives: Blood relatives of the child may be offered participation if one of the following criteria are met:
First-degree blood relatives (e.g., father, sibling) of the child
Second-degree blood relatives (e.g., aunt, uncle, grandparent, half-sibling) of the child
Any more distant male or female blood relative whose data or samples may be informative for the planned genetic studies of hemophilia and inhibitors

Exclusion Criteria

/Discontinuation Criteria: Maternal: For the pregnant person, exclusion or discontinuation criteria are as follows:
Genetic testing is negative for a severe hemophilia A genotype
Prenatal clinical diagnostic testing that indicates there is no fetus affected with severe hemophilia A
Presence of another clinically significant bleeding disorder
Participation in another study for which any blood collection total would exceed safety limits defined in this study
Will deliver outside the United States or plans for regular pediatric care for the child to be delivered outside the United States
Is a prisoner
Any other reason that, in the opinion of the investigator, would render the individual unsuitable for participation in the study
Inability for study team to obtain translated study documents in time for participation if participant is not fluent in English Pediatric: For the child, discontinuation criteria are as follows:
Infant does not have severe hemophilia A defined by a baseline FVIII:C \< 0.01 IU/mL (or FVIII:C \< 1%) or does not have a genotype predicted to cause severe hemophilia A
Mother or child did not have minimal required study samples or data collected before birth, around the time of delivery, or in the neonatal period
Child has another clinically significant bleeding disorder
Child has a clinically severe immune disorder
Participation in another study for which any blood collection total would exceed safety limits defined in this study
Any other reason that, in the opinion of the investigator, would render the individual unsuitable for participation in the study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Seattle?

Yes, this clinical trial (NCT07414511) has an active research site in Seattle, WA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hemophilia A Treatment Options in Seattle, WA

If you're searching for hemophilia a treatment options in Seattle, WA, this clinical trial (NCT07414511) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Seattle research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hemophilia a specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hemophilia a clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Hypertension Trials in Seattle, WA

See all pulmonary hypertension clinical trials recruiting in Seattle — not just this study.

Browse Pulmonary Hypertension Trials in Seattle →

Browse More Trials by Condition

Pulmonary Hypertension TrialsHemophilia TrialsAll Conditions →

Ready to Join in Seattle?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Seattle, WA